Javascript must be enabled to continue!
Molecular and clinicopathological characterization of a prognostic immune gene signature associated with MGMT methylation in glioblastoma
View through CrossRef
Abstract
Background
O6-methylguanine-DNA methyltransferase (MGMT) methylation status affects tumor chemo-resistance and the prognosis of glioblastoma (GBM) patients. We aimed to investigate the role of MGMT methylation in the regulation of GBM immunophenotype and discover an effective biomarker to improve prognosis prediction of GBM patients.
Methods
A total of 769 GBM patients with clinical information from five independent cohorts were enrolled in the present study. Samples from the Cancer Genome Atlas (TCGA) dataset were used as the training set, whereas transcriptome data from the Chinese Glioma Genome Atlas (CGGA) RNA-seq, CGGA microarray, GSE16011, and the Repository for Molecular Brain Neoplasia (REMBRANDT) cohort were used for validation. A series of bioinformatics approaches were carried out to construct a prognostic signature based on immune-related genes, which were tightly related with the MGMT methylation status. The influence of the signature on immunosuppression and remodeling of the tumor microenvironment were comprehensively investigated. Then, the utility of this immune gene signature was analyzed by the development and evaluation of a nomogram.
Results
We found that MGMT unmethylation was closely associated with immune-related biological processes in GBM. Sixty-five immune genes were more highly expressed in the MGMT unmethylated than the MGMT methylated group. An immune gene-based risk model was further established to divide patients into high and low-risk groups, and the prognostic value of this signature was validated in several GBM cohorts. Functional analyses manifested a universal up-regulation of immune-related pathways in the high-risk group as compared to the low-risk group. Furthermore, the risk score was highly correlated to the immune cell infiltration, immunosuppression, inflammatory activities, as well as the expression levels of immune checkpoints. Finally, a nomogram was developed for clinical application.
Conclusions
MGMT methylation is strongly related to the immune responses in GBM. The immune gene-based signature we identified may have potential implications in predicting the prognosis of GBM patients and mechanisms underlying the role of MGMT methylation.
Title: Molecular and clinicopathological characterization of a prognostic immune gene signature associated with MGMT methylation in glioblastoma
Description:
Abstract
Background
O6-methylguanine-DNA methyltransferase (MGMT) methylation status affects tumor chemo-resistance and the prognosis of glioblastoma (GBM) patients.
We aimed to investigate the role of MGMT methylation in the regulation of GBM immunophenotype and discover an effective biomarker to improve prognosis prediction of GBM patients.
Methods
A total of 769 GBM patients with clinical information from five independent cohorts were enrolled in the present study.
Samples from the Cancer Genome Atlas (TCGA) dataset were used as the training set, whereas transcriptome data from the Chinese Glioma Genome Atlas (CGGA) RNA-seq, CGGA microarray, GSE16011, and the Repository for Molecular Brain Neoplasia (REMBRANDT) cohort were used for validation.
A series of bioinformatics approaches were carried out to construct a prognostic signature based on immune-related genes, which were tightly related with the MGMT methylation status.
The influence of the signature on immunosuppression and remodeling of the tumor microenvironment were comprehensively investigated.
Then, the utility of this immune gene signature was analyzed by the development and evaluation of a nomogram.
Results
We found that MGMT unmethylation was closely associated with immune-related biological processes in GBM.
Sixty-five immune genes were more highly expressed in the MGMT unmethylated than the MGMT methylated group.
An immune gene-based risk model was further established to divide patients into high and low-risk groups, and the prognostic value of this signature was validated in several GBM cohorts.
Functional analyses manifested a universal up-regulation of immune-related pathways in the high-risk group as compared to the low-risk group.
Furthermore, the risk score was highly correlated to the immune cell infiltration, immunosuppression, inflammatory activities, as well as the expression levels of immune checkpoints.
Finally, a nomogram was developed for clinical application.
Conclusions
MGMT methylation is strongly related to the immune responses in GBM.
The immune gene-based signature we identified may have potential implications in predicting the prognosis of GBM patients and mechanisms underlying the role of MGMT methylation.
Related Results
Epigenetic regulation of O6-methylguanine-DNA methyltransferase gene expression by histone acetylation and methyl-CpG binding proteins
Epigenetic regulation of O6-methylguanine-DNA methyltransferase gene expression by histone acetylation and methyl-CpG binding proteins
Abstract
Transcriptional silencing of the DNA repair gene, O6-methylguanine-DNA methyltransferase (MGMT) in a proportion of transformed cell lines is associated with...
O6-Methylguanine-DNA Methyltransferase (MGMT) promoter methylation status of high-grade and low-grade gliomas
O6-Methylguanine-DNA Methyltransferase (MGMT) promoter methylation status of high-grade and low-grade gliomas
Background: O6-methylguanine-DNA methyltransferase (MGMT) is a DNA-repair enzyme that correlates with tumor resistance mechanism to chemotherapy. Methylation of the MGMT promoter i...
Prognostic Significance and Clinicopathological Correlations of Epigenetic MGMT Gene Silencing in High Grade Diffuse Gliomas: Experience from a Tertiary Care Centre
Prognostic Significance and Clinicopathological Correlations of Epigenetic MGMT Gene Silencing in High Grade Diffuse Gliomas: Experience from a Tertiary Care Centre
Glioblastoma is the most aggressive and commonest primary malignant brain tumour. Current standard of care includes surgery, radiation, and alkylating agent chemotherapy. Despite m...
MGMT Promoter Methylation as a Prognostic Factor in Primary Glioblastoma: A Single-Institution Observational Study
MGMT Promoter Methylation as a Prognostic Factor in Primary Glioblastoma: A Single-Institution Observational Study
Glioblastoma is the most malignant central nervous system tumor, which represents 50% of all glial tumors. The understanding of glioma genesis, prognostic evaluation, and treatment...
Investigating the role of the apelinergic system in glioblastoma
Investigating the role of the apelinergic system in glioblastoma
<p>Elucidating the molecular signalling circuitry that underpins the pathogenesis of cancers is critical to understanding and developing effective treatment paradigms for can...
Abstract 1524: Overcoming temozolomide resistance in MGMT positive glioblastoma by targeting ALDH1
Abstract 1524: Overcoming temozolomide resistance in MGMT positive glioblastoma by targeting ALDH1
Abstract
Despite aggressive therapy, including radical surgical resection, radiation, and chemotherapy, the prognosis for patients with glioblastoma (GBM) remains po...
Increased life expectancy of heart failure patients in a rural center by a multidisciplinary program
Increased life expectancy of heart failure patients in a rural center by a multidisciplinary program
Abstract
Funding Acknowledgements
Type of funding sources: None.
INTRODUCTION Patients with heart failure (HF)...
Glioblastoma recurrence and the role of MGMT promoter methylation
Glioblastoma recurrence and the role of MGMT promoter methylation
Abstract
Tumor recurrence in glioblastoma multiforme (GBM) is often attributed to acquired resistance to the standard chemotherapeutic agent temozolomide (TMZ). Pro...

